Skeletal Muscle Aging and Responsiveness in Aged People With MS
Skeletal Muscle Aging and Responsiveness in Aged People With MS
What it found
No result yet.
What was tested
Treatment tested
- Exercise trial consisting of both cardiovascular and strength training
What it measured
Main measures
fMQ
Week -3 and Week -2
Physical functionCRF
Enrollment to end of study at 18 weeks
Other measures (18)
Total and Regional Body Composition
Week -3 and Week -2
Blood or spinal fluid markersPhysical functionMuscle Biopsy
Week 1 and Week 12 Muscle Biopsy
Skeletal Muscle Phenotyping
Week 0, 6, and 12
VisionSystemic Inflammation
Week 1 and Week 12
Blood or spinal fluid markersImmune responseMuscle Inflammation
Week 1 and Week 12
Immune responseBlood Biomarkers
Week 1 and Week 12
Blood or spinal fluid markersMobility and Balance
Week -3 and Week -2
Walking and mobilityBasic Cognitive Function and Balance
Week -3 and Week -2
Thinking and memoryWalking and mobilityParticipant's Self Evaluation of Physical, Mental, and Social Health
Week -3 and Week -2
PainQuality of life (reported by participants)Depression
Week -3 and Week -2
Mood and sleep
Who could take part
MS (type not specified) · 60 and over · EDSS 2 to 5.5
Show the full criteria
Inclusion criteria
* 1. Male or female aged 60 or above 2. Free of unmanaged chronic diseases other than multiple sclerosis 3. No structured exercise program (2 or more bouts/wk) within previous 6 months 4. Cognitively capable of providing informed consent 5. Must meet EDSS score between 2 to 5.5 during screening
Exclusion criteria
* 1. Neuromuscular or musculoskeletal disorder, other than multiple sclerosis, that would limit the ability to perform the exercise and/or testing bouts. 2. Cardiopulmonary disorders or reduced breathing capacity 3. Metabolic diseases including markers of liver disease (ALT > 52 U/dl) and type 2 diabetes (HbA1C ≥ 6.5, fasting blood glucose ≥ 126 mg/dl) 4. Taking any dose of metformin 5. Any other disease or disorder that would influence exercise response (e.g., chronic kidney disease, Alzheimer's, current cancer diagnosis or within 2 yr remission, cerebrovascular) 6. History of Chemotherapy within 5 years 7. Unchangeable anticoagulant (Coumadin, Pradaxa, etc.) use. To be determined by clinical staff. 8. Insulin sensitizing/blood glucose lowering (e.g., metformin) or metabolic (GLP1 agonists) drugs. 9. High dose statin (40 mg and above) 10. Have a non-correctable visual impairment 11. Score less than 29 on the Symbol Digit Test 12. Received Botox for spasticity within the prior 3 months of study participation. 13. Cannot have any adjustments to Baclofen during study participation. 13. Unable to commit to \~4 months required to complete the study. 14. Lidocaine allergy 15. Tobacco use 16. Excessive alcohol consumption (3 drinks/d or 7 drinks/wk for females; 4 drinks/day or drinks/wk for males) 17. BMI greater than 35.0 kg/m2
As registered. Criteria can change, so ask the trial team or your neurologist.
Contact details on the registryAbout this trial
In the sponsor's words
The purposes of this study are to: 1) compare baseline muscle and cardiovascular health in older individuals (>60 years old) diagnosed with MS to age-matched people without MS, 2) determine muscle and whole body changes to an exercise training program, 3) determine if the muscle in a more affected leg in individuals diagnosed with MS is different from the muscle of a less affected leg, and 4) if or how individuals diagnosed with MS adapt differently than age-matched people without MS to exercise training. Participation in this study will average 1.5 hours per visit, 3 visits per week, for approximately 4 months.
Papers
Background
Long DE, Peck BD, Lavin KM, Dungan CM, Kosmac K, Tuggle SC, Bamman MM, Kern PA, Peterson CA. Skeletal muscle properties show collagen organization and immune cell content are associated with resistance exercise response heterogeneity in older persons. J Appl Physiol (1985). 2022 Jun 1;132(6):1432-1447. doi: 10.1152/japplphysiol.00025.2022. Epub 2022 Apr 28.Background
Abbott CB, Lawrence MM, Kobak KA, Lopes EBP, Peelor FF 3rd, Donald EJ, Van Remmen H, Griffin TM, Miller BF. A Novel Stable Isotope Approach Demonstrates Surprising Degree of Age-Related Decline in Skeletal Muscle Collagen Proteostasis. Function (Oxf). 2021 May 10;2(4):zqab028. doi: 10.1093/function/zqab028. eCollection 2021.Background
Fuqua JD, Lawrence MM, Hettinger ZR, Borowik AK, Brecheen PL, Szczygiel MM, Abbott CB, Peelor FF 3rd, Confides AL, Kinter M, Bodine SC, Dupont-Versteegden EE, Miller BF. Impaired proteostatic mechanisms other than decreased protein synthesis limit old skeletal muscle recovery after disuse atrophy. J Cachexia Sarcopenia Muscle. 2023 Oct;14(5):2076-2089. doi: 10.1002/jcsm.13285. Epub 2023 Jul 14.Background
Miller B, Hamilton K, Boushel R, Williamson K, Laner V, Gnaiger E, Davis M. Mitochondrial respiration in highly aerobic canines in the non-raced state and after a 1600-km sled dog race. PLoS One. 2017 Apr 26;12(4):e0174874. doi: 10.1371/journal.pone.0174874. eCollection 2017.Background
Bubak MP, Davidyan A, O'Reilly CL, Mondal SA, Keast J, Doidge SM, Borowik AK, Taylor ME, Voloviceva E, Kinter MT, Britton SL, Koch LG, Stout MB, Lewis TL Jr, Miller BF. Metformin treatment results in distinctive skeletal muscle mitochondrial remodeling in rats with different intrinsic aerobic capacities. Aging Cell. 2024 Sep;23(9):e14235. doi: 10.1111/acel.14235. Epub 2024 Jun 24.Background
Graham ZA, Bubak MP, Raymond-Pope CJ, Cutter GR, McAdam JS, Tuggle SC, Siedlik JA, de Sousa LGO, Chappe EJ, Meece K, Kaur A, Ruiz BS, Bamman SC, Vanselow KM, Perry TW, Acosta-Arreguin JS, Bohmke NJ, Addison GJ, Bowers JM, Wright RL, Fuentes LD, Smith JE, Esser KA, Miller BF, Bodine SC, Bamman MM. Multidimensional Modeling to Maximize Adaptations to eXercise: the M3AX trial rationale and study desiBackground
Roberts BM, Lavin KM, Many GM, Thalacker-Mercer A, Merritt EK, Bickel CS, Mayhew DL, Tuggle SC, Cross JM, Kosek DJ, Petrella JK, Brown CJ, Hunter GR, Windham ST, Allman RM, Bamman MM. Human neuromuscular aging: Sex differences revealed at the myocellular level. Exp Gerontol. 2018 Jun;106:116-124. doi: 10.1016/j.exger.2018.02.023. Epub 2018 Feb 24.Background
Lee J, Song RJ, Musa Yola I, Shrout TA, Mitchell GF, Vasan RS, Xanthakis V. Association of Estimated Cardiorespiratory Fitness in Midlife With Cardiometabolic Outcomes and Mortality. JAMA Netw Open. 2021 Oct 1;4(10):e2131284. doi: 10.1001/jamanetworkopen.2021.31284.Background
Gaemelke T, Pedersen IS, Dalgas U, Hvid LG. Sarcopenia in older people with multiple sclerosis: A cross-sectional study. Mult Scler Relat Disord. 2025 Jan;93:106190. doi: 10.1016/j.msard.2024.106190. Epub 2024 Nov 25.Background
Powers SK, Lynch GS, Murphy KT, Reid MB, Zijdewind I. Disease-Induced Skeletal Muscle Atrophy and Fatigue. Med Sci Sports Exerc. 2016 Nov;48(11):2307-2319. doi: 10.1249/MSS.0000000000000975.
Loading reviews and guidelines…
History
Started
Mar 2026
Main results due
Dec 2026
Finished
Dec 2026